Multiple myeloma (MM) accounts for around 15% of new cases and 20% of deaths amongst patients diagnosed with haematological malignancy. To date, few risk factors have been robustly confirmed for MM, these include increasing age, male sex, black race and a family history of MM.
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High body mass index (BMI) has been reported to be associated with an increased risk of MM in several observational studies, though questions remain regarding the aetiological relevance, including the distribution of body fat. 2 In addition to being a potential risk factor for MM, some, but not all, studies have suggested an association between BMI and prognosis. 1, 3 A recent study has suggested the relationship between BMI and MM may be through reduced levels of plasma adiponectin, the inflammatory mediator secreted by adipocytes. The association was, however, confined to obese individuals providing an argument against a direct causal link. 4 Findings such as these, alongside the conflicting results of previous studies into adiposity traits, highlight the limitations of observational studies. Importantly, such studies do not establish a causal relationship, as they cannot fully eliminate the influence of confounding factors. Moreover, in the context of prognostication, many studies have not explicitly addressed the issue of reverse causation. 5 Mendelian randomisation (MR) provides an attractive alternative to the traditional epidemiological study for examining relationships between exposure and disease. MR makes use of allelic variants, which are randomly assigned during meiosis and are robustly associated with traits of interest, as instrumental variables (IVs) to infer whether associations between exposure and disease are causal. The use of these genetically defined IVs as proxies of modifiable exposure, avoids confounding by environmental factors, can be reflective of life-long exposure and circumvents reverse causality.
Genome-wide association studies (GWAS) have identified singlenucleotide polymorphisms (SNPs) at multiple independent loci significantly associated with BMI, childhood obesity (CHO) and plasma levels of adiponectin. [6] [7] [8] Here we have sought to establish a causal association between adiposity traits and MM by performing a MR analysis using SNPs associated with body mass index (BMI), hip circumference adjusted for BMI (HipadjBMI), waist circumference adjusted for BMI (WCadjBMI), waist-to-hip ratio adjusted for BMI (WHRadjBMI), CHO and plasma adiponectin levels as IVs.
We constructed genetic risk scores (GRS), to investigate the relationship of adiposity and plasma levels of adiponectin with MM risk, using the data from five reported MM GWASs, comprising 6 839 cases and 22 221 controls. 9 We performed two-stage MR analysis to assess the association between each adiposity trait and MM using summary statistics from the MM GWAS, and the published effect size of the adiposity trait. As per Burgess et al., 10 a fixed-effects model was used to calculate combined ratio estimates, β, for the effect of each trait on MM risk. Results are summarised in Table 1 .
Following calculation of combined ratio estimates, β, in three of the five cohorts, a positive association was shown between one s. d. in BMI (kg /m 2 ) and MM risk, with the UK-GWAS series being nominally significant ( Figure 1a ). Meta-analysis of the data from all five cohorts did not, however, provide evidence for a causal association (odds ratio (OR) = 1.17, 95% confidence intervals (CIs): 0.92-1.49, P = 0.19). Similarly, we found no association between the other anthropometric traits, which report on central obesity and MM risk, specifically-HipadjBMI, WCadjBMI, WHRadjBMI, which had respective ORs of 0.77 (95% CI: 0.42-1.41), 0.62 (95% CI: 0.37-1.02) and 0.82 (95% CI: 0.57-1.19) (Figures 1b-d) . We also found no support for a relationship between CHO and MM risk (OR = 0.98, 95% CI: 0.87-1.10; Figure 1e ). We then evaluated the impact of plasma levels of adiponectin on the risk of developing MM, again observing no association (OR = 1.04, 95% CI: 0.64-1.72; Figure 1f ). Linkage of the survival data to genotypes on three of the series allowed the relationship between the aforementioned adiposityrelated traits and patient outcome to be examined through MR. In meta-analyses of these data, no association between any of the traits and either overall survival (OS) or progression-free survival (PFS) was shown.
The results from our study contrast with some observational epidemiological studies, which have shown a positive association between adiposity and MM risk and mortality. 1, 11 A recent metaanalysis of studies found a modest, but significant association between BMI and risk in prospective cohorts. 11 Reported relative risks for MM associated with obesity from these studies had OR 95% CIs of 1.08-1.35. Over this range of effect, we had 16-97% study power to demonstrate an association. Hence, we cannot exclude the possibility that the null results we observed were simply a consequence of limited study power if the true effect is marginal.
Obesity is a well-established risk factor for a number of other solid cancers. 12 By inference, it is likely a priori that obesity will also increase MM risk. An elevated level of insulin-like growth factor 1, associated with chronic hyperinsulinemia, stimulates cell proliferation and inhibits apoptosis, therefore providing a biological basis for obesity having a generic effect on cancer risk. 13 In the case of MM, the insulin receptor is overexpressed in MM cells and is increased throughout normal plasma cell differentiation. 14 These observations would therefore imply a causative effect of obesity and ensuing hyperinsulinemia on plasma and myeloma cell growth; a corollary of this may be increased risk of MM and adverse patient outcome.
Our MR analysis does not suffer from the influence of recall bias and confounding that can affect observational studies. 5 Nevertheless, a central assumption in MR is that the variants used as IVs are associated with the exposure being investigated. To ensure this was the case, we only used SNPs associated with adiposityrelated traits at genome-wide significance from GWAS. Furthermore, we only used the data from individuals of European descent to limit bias from population stratification. An additional assumption is that the variants are associated with MM only through the exposure and are not confounded by pleiotropy. We assessed the impact of possible pleiotropism on MR estimates using both inverse variance weighted (IVW) and MR-Egger regression tests as per Bowden et al. 15 Neither test provided evidence for pleiotropy, with respective P-values of 0.2 and 0.71 for BMI, 0.77 and 0.65 for CHO, 0.56 and 0.52 for HipadjBMI, 0.13 and 0.66 for WCadjBMI, 0.4 and 0.79 for WHRadjBMI, and 0.87 and 0.2 for adiponectin plasma levels. While we found no evidence that the SNPs violated this IV assumption, this does not exclude confounding by as yet unidentified confounders.
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